DDS Dental Technology Partners with Identillect’s Delivery Trust® to Secure Email Communications for their Dental Clients
Delivery Trust® Increases Partnerships Providing Secure Communications for Dental Support Organizations (DSO’s) and Managed Service Providers (MSP’s)
IRVINE, Calif., June 21, 2018 (GLOBE NEWSWIRE) -- Identillect Technologies Corp. (the "Company" or "Identillect") (TSX-V:ID) (OTCQB:IDTLF) (Frankfurt:8ID), a trusted leading provider of HIPAA compliant email security, announced today DDS Dental Technology has selected Delivery Trust® to secure email communications for their dental customers to guarantee HIPAA compliant communication.
DDS Dental Technology Inc. provides the best available technology solutions to dentists, at the best rate. They also help evaluate everything, from existing hardware, upgrades, security, and encrypted backup service, anti-virus, malware protection, and secure communication. Their services are designed exclusively for dentists in the Chicago area. They work with customers to create a secure IT infrastructure meeting all technology requirements.
Riju Alex, Operations Manager of DDS Dental Technology states, “DDS Dental Technology proudly serves the Chicago Dental Community for their IT and security needs. We are excited about the partnership with Identillect Technologies to assist our clients on meeting rigorous HIPAA standards. Delivery Trust will ensure the simplest experience for our clients and streamline the secure recipient process.”
HIPAA Journal recently showed email is one of the most vulnerable ways to communicate due to the cyber-attacks being experienced which includes social engineering, phishing attacks and misdirected emails. Email communication was the second most common location of breached PHI. There’s a myth that including a confidentiality notice or disclaimer in an email makes the email compliant with HIPAA and allows a dentist to send PHI via unencrypted or unsecure email. The myth is false. Even the best-worded notice or disclaimer will not make an unencrypted email comply with HIPAA.
Todd Sexton, CEO of Identillect Technologies comments, “Dental Service Organizations such as DDS Dental Technology provide an invaluable service to their customers by advancing technology for practices of all sizes. Identillect has continued to make a significant impact with these organizations by securing all their client communication and we are seeing a significant rise in our user base in the dental community. We are proud to be partnering with such a quality organization like DDS Dental and anticipate continued growth with similar firms throughout 2018.”
On Behalf of the Board of Directors of:
IDENTILLECT TECHNOLOGIES CORP.
Todd Sexton
Chief Executive Officer
Tel: (949) 468-7878
Email: todd.sexton@identillect.com
About Identillect
Identillect Technologies is the leading provider of email encryption service Delivery Trust®, empowering enterprises of all sizes to protect their business and their client’s critical information against cyber security attacks.
Delivery Trust® is an award-winning, multi-platform plug-in, which gives users complete control of their emails, for one low price. One simple integration complies with all regulations and most importantly provides peace of mind.
For more information, or your free trial, please visit www.identillect.com
About DDS Dental Technology
DDS Dental Technology Inc. is a private firm committed to provide the best available technology solutions primarily for dental offices. Our services are designed exclusively for dentists in the Chicago land area. We work with our customers to create a secure IT infrastructure.
Our mission is to provide the best technology solutions at a very affordable rate. As a complete IT and technical solutions provider, we have extensive expertise that allow us to consistently deliver cost-effective hardware and leading solutions to your business on time and within budget. We also help evaluate everything from existing hardware to potential upgrades, paperless initiatives, security, and backup service that is encrypted, anti-virus and malware protection, cabling, and more.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
© 2018 GlobeNewswire, Inc. All Rights Reserved.
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
